Thermo Fisher Scientific Inc. (NYSE:TMO) Holdings Reduced by Bokf Na

BOKF NA lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 8.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,404 shares of the medical research company's stock after selling 2,683 shares during the period. BOKF NA's holdings in Thermo Fisher Scientific were worth $15,946,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Principal Financial Group Inc. lifted its stake in Thermo Fisher Scientific by 22.1% in the 3rd quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company's stock valued at $771,876,000 after buying an additional 225,568 shares in the last quarter. Nordea Investment Management AB boosted its stake in shares of Thermo Fisher Scientific by 23.6% during the fourth quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company's stock valued at $28,868,000 after acquiring an additional 10,606 shares during the last quarter. Kings Path Partners LLC raised its stake in Thermo Fisher Scientific by 13.1% in the 4th quarter. Kings Path Partners LLC now owns 2,637 shares of the medical research company's stock valued at $1,372,000 after purchasing an additional 306 shares during the last quarter. Doliver Advisors LP lifted its holdings in Thermo Fisher Scientific by 1.6% in the 4th quarter. Doliver Advisors LP now owns 2,803 shares of the medical research company's stock valued at $1,458,000 after purchasing an additional 44 shares in the last quarter. Finally, Oliver Luxxe Assets LLC grew its holdings in shares of Thermo Fisher Scientific by 6.2% during the fourth quarter. Oliver Luxxe Assets LLC now owns 9,461 shares of the medical research company's stock worth $4,922,000 after buying an additional 555 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have commented on TMO shares. Wells Fargo & Company lowered their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research note on Thursday, April 24th. Morgan Stanley upped their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. Evercore ISI lowered their price target on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Citigroup decreased their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Finally, UBS Group dropped their price target on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Five analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $607.43.

Insider Buying and Selling

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares of the company's stock, valued at $5,759,736.32. This trade represents a 25.87 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now directly owns 23,167 shares in the company, valued at approximately $9,960,188.31. This represents a 1.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 14,075 shares of company stock worth $7,305,942. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Down 1.9 %

Shares of TMO stock traded down $7.85 on Friday, hitting $402.93. The stock had a trading volume of 2,318,607 shares, compared to its average volume of 1,797,671. Thermo Fisher Scientific Inc. has a 52-week low of $401.87 and a 52-week high of $627.88. The firm has a market capitalization of $152.10 billion, a price-to-earnings ratio of 24.38, a P/E/G ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The stock's 50 day moving average is $466.94 and its 200-day moving average is $516.54.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company's revenue was up .2% on a year-over-year basis. During the same period last year, the firm earned $5.11 earnings per share. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were given a dividend of $0.43 per share. The ex-dividend date was Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.